Status:
COMPLETED
Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The researchers aimed to investigate the effect of point-of-care platelet function assay on the periprocedural cardiac enzyme elevation in patients with diabetes mellitus. All patients who are suppos...
Eligibility Criteria
Inclusion
- Patients who were determined to implant drug-eluting coronary stent
- Diabetes mellitus (type 1 or 2)
Exclusion
- Age \<18 years or \>80years
- Patients with acute myocardial infarction
- Patients with history of cerebral hemorrhage ever or ischemic infarction within 2 years
- Patients with history of major surgery (abdominal, thoracic, intraocular) within 6 months
- Patients who have have allergy to antiplatelet medications (aspirin, clopidogrel, abciximab)
- Patients who are on anticoagulation therapy
- Serum creatinine \>2.0mg/dl or ALT/AST \> 3 times of upper normal limit (120 U/L)
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT01475552
Start Date
September 1 2010
End Date
October 1 2011
Last Update
December 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam, South Korea